Almirall account plan
Medical Dermatology Solutions
At a glance
Almirall is a Barcelona-based pharmaceutical group focused on medical dermatology, with FY2025 net turnover of €1,108.1 million and 2,108 employees.
Almirall is a pharmaceutical group founded in 1944, headquartered in Barcelona and listed on the Spanish Stock Exchange (ticker ALM), that has refocused its strategy on skin health; its R&D centre is dedicated exclusively to skin health. Its growth comes from European medical dermatology (Ebglyss, Ilumetri, Wynzora, Klisyri), complemented by legacy respiratory, gastrointestinal, central nervous system, cardiovascular and musculoskeletal products. FY2025 net turnover was €1,108.1 million (+12.4%) and consolidated net profit €46.2 million, against €10.1 million in 2024. It had 2,108 employees at end-2025, 96% of them in Europe, and runs plants in Sant Andreu de la Barca, Sant Celoni (Spain) and Reinbek (Germany). The Gallardo family controls it through Grupo Plafin (44.3%) and Grupo Corporativo Landon (15.6%), and Carlos Gallardo Piqué is Chairman and CEO.
Business units
Dermatology and others
about 60% of FY2025 net turnover (€669.4 million)The core of the strategy: treatments for skin diseases sold to dermatologists, mainly in Europe, led by the biologics Ebglyss (atopic dermatitis) and Ilumetri (plaque psoriasis), plus Wynzora and Klisyri. European Dermatology grew 17.6% to €520.3 MM in the first nine months of 2026.
Respiratory
about 9% of FY2025 net turnover (€100.1 million)Part of the legacy, non-dermatology portfolio that complements the skin-health lines; turnover rose from €92.7 million in 2024.
Gastrointestinal and metabolism
about 8% of FY2025 net turnover (€90.7 million)Legacy portfolio, down from €98.2 million in 2024; Almirall divested Algidol and the Sekisan licence in Spain in January 2025.
Central nervous system
about 8% of FY2025 net turnover (€89.6 million)Legacy therapeutic division, up from €82.4 million in 2024.
Cardiovascular
about 8% of FY2025 net turnover (€85.1 million)Legacy therapeutic division, down from €89.4 million in 2024.
Musculoskeletal
about 3% of FY2025 net turnover (€33.3 million)Legacy therapeutic division, down from €39.8 million in 2024.
Other therapeutic specialities
about 4% of FY2025 net turnover (€39.8 million)Products outside the named therapeutic areas, up from €35.1 million in 2024.
Strategic priorities
- Leadership in European medical dermatology
- European Dermatology net sales grew 25.6% in 2025 and remain the main growth engine; management targets more than EUR 300 million peak sales for Ilumetri and more than EUR 450 million for Ebglyss.
- Mid-term growth and margin targets
- A double-digit net sales CAGR between 2023 and 2030 and an EBITDA margin of around 25% by 2028; 9M 2026 EBITDA was already about 25% of net sales, two years ahead of the 2028 ambition.
- Skin-health pipeline with global rights
- Six PoC/Phase II programmes across five dermatological diseases, including hidradenitis suppurativa, alopecia areata, atopic dermatitis and pyoderma gangrenosum; the first readout is expected in the coming months, the rest during 2027 and early 2028.
- External innovation and partnering
- R&D keeps hypothesis generation in-house and partners for the modality, with deals such as CrystalO, Certest Biotec, Huaota and Wockhardt, and new offices in China.
- Disciplined capital deployment
- Management looks for selective bolt-on M&A and early-stage licensing that fit the medical dermatology strategy, while keeping a prudent financial approach.
Latest results
In the first nine months of 2026, net sales rose 8.3% to €889.2 MM and EBITDA rose 22.7% to €221.7 MM, a 24.9% margin against 22.0% a year earlier. European Dermatology grew 17.6% to €520.3 MM, with Ebglyss at €132.1 MM (+75.0%) and Ilumetri at €190.6 MM (+11.5%); Q3 was Ilumetri's best quarter since launch. Net income was €53.3 MM (+36.3%) and free cash flow EUR 83 million against EUR 42 million. FY2026 guidance of 9-12% net sales growth and €270-290 MM EBITDA was reiterated, with sales expected toward the mid-to-low end of the range and EBITDA toward the upper end. FY2026 results are due on 22 February 2027.
Investments and deals
- R&D spend
- R&D expenses were €138.2 million in 2025 (+11%) and about 12% of net sales in 9M 2026; Almirall has invested more than €1 billion in R&D over the last decade.
- Licensing and research collaborations
- In 2026 Almirall signed a collaboration and licensing deal with Certest Biotec (mRNA/LNP, rare skin diseases), a collaboration with Huaota, and a deal with CrystalO for ion-channel small molecules, and extended its partnership with the Barcelona Supercomputing Center on AI.
- Bond refinancing
- On 17 December 2025 Almirall issued €250 million of senior unsecured bonds at 3.75%, maturing on 15 June 2031; S&P raised the rating to BB+ and Moody's upgraded it to Ba1.
- Milestone and ordinary capex
- Investment capex for licensed-asset milestones will average about EUR 70-75 million a year, and ordinary capex about EUR 70-80 million in 2026.
- Portfolio pruning
- Divestment of Algidol and the Sekisan licence in Spain in January 2025 (€12 million collected) and the Actithiol divestment.
Challenges and risks
- European price and reimbursement pressure
- Price cuts, reimbursement conditions and contributions to health systems may grow with government budget deficits; the German healthcare reform could cost 1% to 2.5% of revenue from 2027, per market estimates.
- Legacy and US portfolio decline
- The legacy non-dermatology portfolio fell 4.6% over nine months of 2026, and US sales declined as Cordran Tape, Tazorac and Aczone face generics and Seysara more competition.
- Pipeline risk
- The report names an R&D pipeline that is not balanced or differentiated enough as a risk, with the first PoC readouts only starting around the end of 2026.
- Supply, cyber and talent risks
- Supply shortages from geopolitical volatility or climate risks, cyberattacks and difficulty attracting and retaining talent are named among the principal risks.
What leadership says
“Our solid results in Q3 are in line with our expectations and our long-term growth trajectory and are being led by the sustained growth of our European Dermatology business and our biologics.”
“we remain disciplined but active on capital deployment”
“We are committed to shaping leadership in medical dermatology in Europe, turning innovation into growth, and delivering lasting value for patients and shareholders.”
“There is still a lot of uncertainty about how this will land.”
Where a supplier can help
- Biologics launch and market access in Europe
- The Ebglyss and Ilumetri peak-sales targets and European price pressure create needs for market access, real-world evidence and HCP engagement services across launch countries.
- Clinical development services
- Six PoC/Phase II programmes, a Phase III in nummular eczema and a Phase IIIb in face and neck atopic dermatitis call for CRO, patient recruitment and trial data capacity.
- Discovery and AI partnerships
- The partner-for-modality R&D model and the extended AI collaboration with the Barcelona Supercomputing Center open doors for discovery platforms and computational biology providers.
- Manufacturing and supply resilience
- Supply shortages are a named risk across plants in Spain and Germany and third-party manufacturers, pointing to supply-chain visibility and contract manufacturing offers.
- Cybersecurity
- Cyberattacks are listed among the principal risks of a group with subsidiaries across Europe, the United States and China.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Almirall?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Consolidated Management Report 2025 (with Annex I Non-Financial and Sustainability Statement)
- Almirall is a Barcelona-headquartered pharmaceutical group founded in 1944, listed on the Spanish Stock Exchange (ticker ALM), that has refocused its strategy on skin health (medical dermatology); its R&D centre is dedicated exclusively to skin health.
- FY2025 net turnover was €1,108.1 million (+12.4%) and operating income €1,114.5 million (+12.5%), driven by European dermatology (Ilumetri, Ebglyss, Wynzora); consolidated net profit rose to €46.2 million from €10.1 million in 2024.
- Dermatology and others brought €669.4 million of net turnover in 2025 (about 60% of the total, computed); the rest comes from legacy therapeutic areas (respiratory, gastrointestinal and metabolism, central nervous system, cardiovascular, musculoskeletal).
- By geography: Europe and Middle East €683.5 million, Spain €328.9 million, America, Asia and Africa €95.6 million; the United States is less than 5% of net turnover.
- R&D expenses were €138.2 million (+11%), driven by the Ichnos and Novo Nordisk agreements; the goal is to have six proof-of-concept studies under way before the end of 2026, and the anti-IL1RAP compound for hidradenitis suppurativa moved to Phase II.
- Balance sheet: cash of €337.8 million at year-end; €250 million of senior unsecured bonds at 3.75% due 2031 issued in December 2025; S&P raised the corporate rating from BB to BB+.
- 2,108 employees at end-2025 (96% in Europe, 4% in the United States); own plants in Sant Andreu de la Barca and Sant Celoni (Spain) and Reinbek (Germany).
- Controlled by the Gallardo family: Grupo Plafin 44.3% and Grupo Corporativo Landon 15.6%; Carlos Gallardo Piqué is Chairman and CEO.
- Key risks named: price and reimbursement pressure in Europe, supply shortages, cyberattacks, impairment of intangibles, an insufficiently differentiated R&D pipeline, and US international reference pricing and tariffs.
- 2026 trends: continued growth of the biologics Ebglyss and Ilumetri, Wynzora and Klisyri expected to keep growing, and management still looking for opportunistic acquisitions with a prudent financial approach.
- Almirall H1 2026 Results
- H1 2026 net sales rose 7.5% to €602.7 MM and EBITDA rose 23.7% to €150.7 MM (25% of sales, against 21.7% in H1 2025).
- The European Dermatology business grew 18.1% to €341.9 MM and remains the growth engine.
- Biologics: Ilumetri €125.2 MM (+10.5%); Ebglyss €84.5 MM (+88.2%), driven by recent launch markets.
- Wynzora €20.4 MM (+19.3%) and Klisyri €15.6 MM (+13.9%).
- Net income €39.6 MM (+49.4%); normalised net income €42.4 MM; gross margin 64.6% of sales (65.5% a year earlier).
- About 11.5% of net sales went to R&D. Four PoC/Phase II studies are running and two more are planned by the end of 2026, across five dermatological diseases; first readouts are expected before year-end.
- New deals: research collaboration and licensing with Certest Biotec (mRNA/LNP, rare skin diseases), a collaboration with China-based Huaota, new offices in China, and an extended partnership with the Barcelona Supercomputing Center on AI.
- FY2026 guidance reiterated: 9-12% net sales growth and EBITDA of €270 MM to €290 MM.
- Almirall 9M 2026 Results
- 9M 2026 net sales rose 8.3% to €889.2 MM, total revenue was €893.6 MM, and EBITDA rose 22.7% to €221.7 MM (24.9% margin, against 22.0%).
- European Dermatology grew 17.6% to €520.3 MM.
- Ebglyss €132.1 MM (+75.0%), with market share rising across launched markets; Ilumetri €190.6 MM (+11.5%).
- Wynzora €29.3 MM (+15.4%) and Klisyri €23.8 MM (+18.4%).
- Net income €53.3 MM (+36.3%); normalised net income €60.6 MM (+45.0%).
- R&D was about 12% of net sales. Six programmes: four in PoC/Phase II and two PoC studies to start near year-end, including pyoderma gangrenosum for the anti-IL-1RAP antibody. First readouts are expected this quarter.
- New collaboration and licensing deal with CrystalO (ion-channel small molecules). 5-year ADlong data for Ebglyss were shown at EADV 2026.
- FY2026 guidance reiterated: 9-12% net sales growth and €270-290 MM EBITDA. FY2026 results are due on 22 February 2027.
- Almirall 9M 2026 Financial Results and Business Update - earnings call transcript
- Carlos Gallardo (Chairman and CEO) said 9M 2026 net sales of EUR 889 million (+8.3%) came in "in line with the trajectory set out at the beginning of the year", with European dermatology "a primary growth engine".
- Ilumetri had its best quarter since launch, with over EUR 65 million in Q3. The more than EUR 300 million peak sales target stands, and the Ebglyss peak sales estimate of more than EUR 450 million was reiterated.
- CFO Jon Garay: 9M EBITDA of EUR 222 million, about 25% of net sales, "two years ahead of our 2028 ambition". FY2026 sales are expected toward the mid-to-low end of the 9-12% range, and EBITDA toward the upper end (around EUR 290 million).
- Net cash to EBITDA was around 0.2x and free cash flow EUR 83 million (EUR 42 million a year earlier). Moody's upgraded Almirall to Ba1, and the balance sheet leaves room for licensing and selective bolt-on acquisitions.
- The German healthcare reform could cost 1% to 2.5% of revenue from 2027, according to market estimates the CEO called "probably this is the best estimate range".
- CSO Karl Ziegelbauer: six PoC/Phase II programmes; the first readout (IL-2 in atopic dermatitis) is expected in the coming months, with the rest during 2027 and early 2028. Early-stage partnering in China (CrystalO, Huaota) is a deliberate strategy.
- The legacy non-dermatology portfolio fell 4.6% over nine months (per the analyst's question). US sales declined, and FX cost 6 percentage points in US dermatology; rest of world is 5% of sales and growing double digits (Finjuve in Asia).
- Almirall Full Year 2025 earnings call transcript
- Carlos Gallardo (Chairman and CEO): 2025 net sales of EUR 1,108 million (+12.4%), near the top of the 10-13% guidance, and EBITDA of nearly EUR 233 million; net sales exceeded EUR 1 billion for the first time.
- 2026 guidance: 9-12% net sales growth (10.5% midpoint) and EBITDA of EUR 270-290 million. Mid-term: double-digit sales CAGR over 2023-2030 and an EBITDA margin of around 25% by 2028.
- Ilumetri reached EUR 234 million (+12%), on track for more than EUR 300 million at peak. Ebglyss more than tripled to EUR 111 million, which the CEO called "the most successful atopic dermatitis launch in recent years".
- CFO Jon Garay: European dermatology net sales grew 25.6%, the US declined on generics and Seysara competition, gross margin was 64.4%, R&D 12.5% of net sales, and net debt to EBITDA 0.
- The low end of the 2026 guide reflects about EUR 12-15 million of 2025 one-offs (Algidol divestment, Sekisan out-licence) that may not be repeated.
- Pipeline: three PoC/Phase II studies under way and three more planned, with readouts from end-2026. All pipeline programmes carry global rights, which the CEO contrasted with European-only rights for Ilumetri.
- Capital allocation: the EUR 250 million bond keeps flexibility for early-stage deals and bolt-on acquisitions; recurring investment capex of about EUR 70-75 million a year for milestones.
Questions about Almirall
What does Almirall do?
Almirall is a Barcelona-based pharmaceutical group focused on skin health. It sells dermatology treatments such as Ebglyss, Ilumetri, Wynzora and Klisyri, mainly in Europe, alongside legacy products in other therapeutic areas.
What is Almirall's revenue?
FY2025 net turnover was €1,108.1 million (+12.4%), the first year above EUR 1 billion. In the first nine months of 2026 net sales were €889.2 MM, up 8.3%.
How many employees does Almirall have?
Almirall had 2,108 employees at end-2025, 96% in Europe and 4% in the United States, with 1,349 in Spain.
Who leads Almirall?
Carlos Gallardo Piqué is Chairman and CEO, with Jon Garay as CFO and Karl Ziegelbauer as Chief Scientific Officer.
What is Almirall's strategy?
It aims at leadership in medical dermatology in Europe, growing its biologics, building a skin-health pipeline with global rights through partnerships, and pursuing selective bolt-on M&A.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)